Siegfried H1 revenue rises on acquisitions, strong service demand
Siegfried H1 revenue rises on acquisitions, strong service demand
Overview
Switzerland contract drug manufacturer’s H1 revenue rose 4.8% in local currencies, beating analyst expectations
Core EBITDA and core net profit increased, with EBITDA margin improving to 22.4%
Company completed acquisition of three drug substance sites in US and Australia
Outlook
Siegfried confirms 2026 sales growth in high-single-digit percentage range in local currencies
Company expects 2026 core EBITDA margin above 23%
Mid-term outlook sees continued profitable growth above market, excluding M&A
Result Drivers
ACQUISITIONS - Co said acquisition of three drug substance sites in US and Australia contributed to growth and strengthened US capacity
DEMAND FOR SERVICES - Co cited sustained demand for development and manufacturing services across drug substances and drug products
OPERATING IMPROVEMENTS - Co attributed higher core EBITDA margin to continuous operating improvements and favorable business mix
Company press release: ID:nEQ9gsfyma
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
H1 Revenue | Beat | CHF 633 mln | CHF 621 mln (3 Analysts) |
H1 Core Net Profit |
| CHF 68.20 mln |
|
H1 Core EBITDA |
| CHF 142 mln |
|
Reuters Recommended Reads
Aug 19 - Switzerland's Straumann slightly beat H1 revenue expectations, maintains guidance
Aug 18 - Switzerland's Basilea H1 revenue rises on Cresemba demand; ups 2026 profit outlook
Aug 19 - Switzerland's DocMorris H1 revenue rises on RX growth, raises 2026 outlook
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)